These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25044219)

  • 81. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
    Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
    J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide.
    Cawello W; Fuhr U; Hering U; Maatouk H; Halabi A
    Clin Pharmacokinet; 2013 Oct; 52(10):897-906. PubMed ID: 23737404
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers.
    Burkhardt O; Borner K; von der Höh N; Köppe P; Pletz MW; Nord CE; Lode H
    J Antimicrob Chemother; 2002 Nov; 50(5):707-12. PubMed ID: 12407127
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Safety and dose-finding study of activated protein C (drotrecogin alfa activated) as an anticoagulant in end-stage renal disease patients treated with hemodialysis.
    Brasha-Mitchell E; Collins A; Shehu L; Seneff MG; Patel SS; Chawla LS
    Blood Purif; 2014; 37(3):243-8. PubMed ID: 24969781
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.
    Zoller M; Maier B; Hornuss C; Neugebauer C; Döbbeler G; Nagel D; Holdt LM; Bruegel M; Weig T; Grabein B; Frey L; Teupser D; Vogeser M; Zander J
    Crit Care; 2014 Jul; 18(4):R148. PubMed ID: 25011656
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.
    Hawi A; Alcorn H; Berg J; Hines C; Hait H; Sciascia T
    BMC Nephrol; 2015 Apr; 16():47. PubMed ID: 25885112
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment.
    Patel G; Rodvold KA; Gupta VK; Bruss J; Gasink L; Bajraktari F; Lei Y; Jain A; Srivastava P; Talley AK
    Antimicrob Agents Chemother; 2022 May; 66(5):e0240721. PubMed ID: 35420493
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.
    Haubitz M; Bohnenstengel F; Brunkhorst R; Schwab M; Hofmann U; Busse D
    Kidney Int; 2002 Apr; 61(4):1495-501. PubMed ID: 11918757
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
    Scoville BA; Segal JH; Salama NN; Heung M; Bleske BE; Eyler RF; Mueller BA
    Ren Fail; 2019 Nov; 41(1):118-125. PubMed ID: 30909832
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Subdural hematoma in patients with end-stage renal disease receiving hemodialysis.
    Wang IK; Lin CL; Wu YY; Kuo HL; Lin SY; Chang CT; Yen TH; Chuang FR; Cheng YK; Huang CC; Sung FC
    Eur J Neurol; 2014 Jun; 21(6):894-900. PubMed ID: 24689932
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure.
    Caltabiano S; Cizman B; Burns O; Mahar KM; Johnson BM; Ramanjineyulu B; Serbest G; Cobitz AR
    Clin Kidney J; 2019 Oct; 12(5):693-701. PubMed ID: 31583094
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients.
    Vandecasteele SJ; Miranda Bastos AC; Capron A; Spinewine A; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2015 Dec; 46(6):660-5. PubMed ID: 26603304
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.
    Kambia NK; Dine T; Odou P; Bah S; Azar R; Gressier B; Dupin-Spriet T; Luyckx M; Brunet C
    Eur J Drug Metab Pharmacokinet; 2004; 29(4):225-30. PubMed ID: 15726882
    [TBL] [Abstract][Full Text] [Related]  

  • 96. GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease.
    Lebherz C; Schlieper G; Möllmann J; Kahles F; Schwarz M; Brünsing J; Dimkovic N; Koch A; Trautwein C; Flöge J; Marx N; Tacke F; Lehrke M
    Am J Med; 2017 Jul; 130(7):833-841.e3. PubMed ID: 28366423
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dialyzability of Faropenem in Infected Patients on Chronic Hemodialysis.
    Hasegawa G; Tsuruoka S; Ushijima K; Maeda A; Hayasaka T; Saito T; Harada K; Fujimura A
    Ther Apher Dial; 2017 Feb; 21(1):52-56. PubMed ID: 27629941
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Troponin I Levels in Asymptomatic Hemodialysis Patients.
    Castini D; Persampieri S; Floreani R; Galassi A; Biondi ML; Carugo S; Cozzolino M
    Blood Purif; 2017; 44(3):236-243. PubMed ID: 28957803
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function.
    Cefali EA; Poynor WJ; Sica D; Cox S
    J Clin Pharmacol; 1991 Sep; 31(9):808-14. PubMed ID: 1804864
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.
    Kamal MA; Lien KY; Robson R; Subramoney V; Clinch B; Rayner CR; Gibiansky L
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6774-81. PubMed ID: 26282419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.